Avidity Partners Management LP — 13F Holdings & Portfolio
CIK 1791827 · latest 13F-HR filed 2026-05-28
Avidity Partners Management LP manages $493.8M in 13F-reported U.S. long-equity assets across 45 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are DNTH (35.76%), CGON (17.67%), ORKA (7.55%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions, exited 7, added to 12, and trimmed 13.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$493.8M
Long-equity book
45
Distinct positions
2026-03-31
Filed 2026-05-28
+6 / −7 / ↑12 / ↓13
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- TEVA PHARM ADR$6.5M +93.3%
- VIR BIOTECHNOLOGY INC$2.2M +34.6%
- PERSPECTIVE THERAPEUTICS INC$1.6M +6.9%
- CONTEXT THERAPEUTICS INC$1.3M +11.0%
- IMMUNIC INC$991.5K +15.4%
Top Trims
- ORUKA THERAPEUTICS INC-$14.7M -28.3%
- JADE BIOSCIENCES INC-$14.5M -42.4%
- TEMPUS AI INC-$2.5M -68.7%
- KARYOPHARM THERAPEUTICS INC-$1.3M -33.0%
- SATELLOS BIOSCIENCE INC-$899.6K -29.2%
New Positions
- CG ONCOLOGY INC$87.2M
- CENTENE CORP$2.3M
- KENVUE INC ORD$1.7M
- REVOLUTION MEDICINES INC$1.5M
- ABIVAX SA-ADR$1.1M
Exited Positions
- HUMANA INC$5.9M
- INSULET CORP$1.7M
- CHARLES RIV LABS INTL INC$1.7M
- ABBOTT LABORATORIES$907.9K
- BRIDGEBIO PHARMA INC$711.1K
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $176.6M | 35.76% | 2,104,184 | SH |
| 2 | CG ONCOLOGY INC | CGON | 156944100 | $87.2M | 17.67% | 1,288,948 | SH |
| 3 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $37.3M | 7.55% | 760,424 | SH |
| 4 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $25.2M | 5.11% | 6,049,999 | SH |
| 5 | JADE BIOSCIENCES INC | JBIO | 008064206 | $19.7M | 3.99% | 1,400,708 | SH |
| 6 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $15.7M | 3.18% | 400,000 | SH |
| 7 | TEVA PHARM ADR | TEVA | 881624209 | $13.6M | 2.75% | 450,100 | SH |
| 8 | CONTEXT THERAPEUTICS INC | CNTX | 21077P108 | $13.1M | 2.65% | 4,998,267 | SH |
| 9 | REPLIGEN CORP | RGEN | 759916109 | $9.2M | 1.86% | 77,800 | SH |
| 10 | PALVELLA THERAPEUTICS INC | PVLA | 697947109 | $8.7M | 1.77% | 70,000 | SH |
| 11 | MEDTRONIC INC | MDT | G5960L103 | $8.7M | 1.75% | 100,000 | SH |
| 12 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $8.5M | 1.72% | 950,000 | SH |
| 13 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $8.4M | 1.70% | 468,566 | SH |
| 14 | IMMUNIC INC | IMUX | 4525EP101 | $7.4M | 1.51% | 6,699,411 | SH |
| 15 | DEXCOM | DXCM | 252131107 | $5.7M | 1.14% | 90,000 | SH |
| 16 | ENCOMPASS HEALTH CORP | EHC | 29261A100 | $4.1M | 0.82% | 42,000 | SH |
| 17 | BOSTON SCIENTIFIC CORPORATION | BSX | 101137107 | $3.8M | 0.76% | 60,000 | SH |
| 18 | TENAX THERAPEUTICS INC | TENX | 88032L605 | $3.5M | 0.70% | 215,934 | SH |
| 19 | GILEAD SCIENCES INC | GILD | 375558103 | $2.8M | 0.56% | 20,000 | SH |
| 20 | PHATHOM PHARMACEUTICALS INC | PHAT | 71722W107 | $2.8M | 0.56% | 249,390 | SH |
| 21 | KARYOPHARM THERAPEUTICS INC | KPTI | 48576U205 | $2.6M | 0.52% | 463,741 | SH |
| 22 | CENTENE CORP | CNC | 15135B101 | $2.3M | 0.46% | 70,000 | SH |
| 23 | SATELLOS BIOSCIENCE INC | MSLE | 80401L803 | $2.2M | 0.44% | 387,769 | SH |
| 24 | SCYNEXIS INC | SCYX | 811292200 | $1.9M | 0.39% | 2,081,660 | SH |
| 25 | NATERA INC | NTRA | 632307104 | $1.8M | 0.36% | 9,000 | SH |
| 26 | ICON PLC | ICLR | G4705A100 | $1.8M | 0.36% | 16,000 | SH |
| 27 | KENVUE INC ORD | KVUE | 49177J102 | $1.7M | 0.35% | 100,000 | SH |
| 28 | CORVUS PHARMACEUTICALS INC | CRVS | 221015100 | $1.7M | 0.34% | 115,000 | SH |
| 29 | HIMS & HERS HEALTH INC | HIMS | 433000106 | $1.6M | 0.32% | 75,000 | SH |
| 30 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $1.5M | 0.30% | 15,000 | SH |
| 31 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $1.4M | 0.29% | 30,000 | SH |
| 32 | GENMAB A/S -SP ADR | GMAB | 372303206 | $1.3M | 0.27% | 50,000 | SH |
| 33 | CORCEPT THERA | CORT | 218352102 | $1.2M | 0.24% | 30,000 | SH |
| 34 | TEMPUS AI INC | TEM | 88023B103 | $1.1M | 0.23% | 25,000 | SH |
| 35 | ABIVAX SA-ADR | ABVX | 00370M103 | $1.1M | 0.23% | 10,000 | SH |
| 36 | UNITEDHEALTH GRP | UNH | 91324P102 | $1.0M | 0.21% | 3,800 | SH |
| 37 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $961.5K | 0.19% | 75,000 | SH |
| 38 | ODDITY TECH LTD-CL A | ODD | M7518J104 | $936.6K | 0.19% | 70,000 | SH |
| 39 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $932.0K | 0.19% | 50,000 | SH |
| 40 | PELOTON INTERACTIVE INC-A | PTON | 70614W100 | $858.0K | 0.17% | 200,000 | SH |
| 41 | ANTERIS TECHNOLOGIES GLOBAL | AVR | 03675P102 | $832.5K | 0.17% | 150,000 | SH |
| 42 | ARBUTUS BIOPHARMA CORP | ABUS | 03879J100 | $562.5K | 0.11% | 125,000 | SH |
| 43 | BRIDGEBIO ONCOLOGY THERAPEUTIC | BBOT | 107924102 | $392.5K | 0.08% | 43,853 | SH |
| 44 | ACADIA PHARM | ACAD | 004225108 | $288.6K | 0.06% | 12,967 | SH |
| 45 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $79.5K | 0.02% | 6,660 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | $441.9M | 46 | 0001791827-26-000003 |
| 2026-03-31 | 2026-05-28 | $493.8M | 45 | 0001791827-26-000004 |
| 2025-12-31 | 2026-02-13 | $346.7M | 39 | 0001791827-26-000002 |
| 2025-09-30 | 2025-11-14 | $439.4M | 43 | 0001791827-25-000008 |